RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myeloma

Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311–20. CAS Article Google Scholar Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:754–66. CAS Article Google Scholar Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood. 2008;112:2489–99. CAS Article Google Scholar Robak P, Drozdz I, Szemraj J, Robak T. Drug resistance in multiple myeloma. Cancer Treat Rev. 2018;70:199–208. CAS Article Google Scholar Balsas P, Galan-Malo P, Marzo I, Naval J. Bortezomib resistance in a myeloma cell line is associated to PSMbeta5 overexpression and polyploidy. Leuk Res. 2012;36:212–8. CAS Article Google Scholar Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Anderson KC, Richardson PG. The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev. 2017;36:561–84. CAS Article Google Scholar Huang J, Zhou Y, Thomas GS, Gu Z, Yang Y, Xu H, et al. NEDD8 inhibition overcomes CKS1B-induced drug resistance by upregulation of p21 in multiple myeloma. Clin Cancer Res. 2015;21:5532–42. CAS Article Google Scholar Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005;106:296–303. CAS Article Google Scholar Kato S, Ding J, Pisck E, Jhala U, Du K. COP1 functions as a FoxO1 ubiquitin E3 ligase to regulate FoxO1-mediated gene expression. J Biol Chem. 2008;283:35464–73. CAS Article Google Scholar Choi HH, Guma S, Fang L, Phan L, Ivan C, Baggerly K, et al. Regulating the stability and localization of CDK inhibitor p27(Kip1) via CSN6-COP1 axis. Cell Cycle. 2015;14:2265–73. CAS Article Google Scholar Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood. 2006;108:2020–8. CAS Article Google Scholar Pernet CR, Wilcox RR, Rousselet GA. Robust correlation analyses: false positive and power validation using a new open source matlab toolbox. Front Psychol. 2013;3:606. Article Google Scholar Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A, et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood. 2010;116:2543–53. CAS Article Google Scholar Zhan F, Colla S, Wu X, Chen B, Stewart JP, Kuehl WM, et al. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood. 2007;109:4995–5001. CAS Article Google Scholar Kuiper R, Broyl A, de Knegt Y, van Vliet MH, van Beers EH, van der Holt B, et al. A gene expression signature for high-risk multiple myeloma. Leukemia. 2012;26:2406–13. CAS Article Google Scholar Download references This work was supported by National Key Research and Development Program-precision medicine sub-program 2016YFC0905900 (to YY); National Natural Science Foundation of China 81970196 (to CG), 81670200 (to YY); The Priority Academic Program Development of Jiangsu Higher Education Institutions for Chinese Medicine. These authors contributed equally: Chunyan Gu, Ting Lu The Third Affiliated Hospital, Nanjing University of Chinese Medicine, Nanjing, China Chunyan Gu, Wang Wang, Rongfang Wei, Mengjie Guo, Rui Li, Li Qiao \u0026 Ye Yang School of Medicine \u0026 Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China Chunyan Gu, Ting Lu, Wang Wang, Miaomiao Shao, Rongfang Wei, Mengjie Guo, Rui Li, Li Qiao, Ye Hu \u0026 Ye Yang Key Laboratory for Combination of Acupuncture and Chinese Materia Medica of Chinese Ministry of Education, Nanjing University of Chinese Medicine, Nanjing, China Chunyan Gu, Wang Wang, Rongfang Wei, Mengjie Guo, Rui Li, Li Qiao \u0026 Ye Yang Internal Medicine, University of Iowa, Iowa City, IA, USA Fenghuang Zhan \u0026 Ye Yang Laboratory of Hematology and Immunology \u0026 Labor fur Myelomforschung, Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090, Jette, Belgium Anja Seckinger \u0026 Dirk Hose You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar Correspondence to Ye Yang. No potential conflicts of interest were disclosed. Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Reprints and Permissions Gu, C., Lu, T., Wang, W. et al. RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myeloma. Leukemia (2020). https://doi.org/10.1038/s41375-020-01033-z Download citation Received: 03 February 2020 Revised: 12 August 2020 Accepted: 17 August 2020 Published: 08 September 2020 DOI: https://doi.org/10.1038/s41375-020-01033-z